Keywords: Merck & Co, Mylan, Patent appeal, Zetia, Vytorin, GlaxoSmithKline, Trametinib, Dabraffenib, BRAF/MEK, Metastatic melanoma, EU filing

Merck & Co prevails in patent fight over Zetia and Vytorin; GSK files for EU approval of melanoma products

Article | 08 February 2013

Print This

US pharma giant Merck & Co (NYSE: MRK) has received a favorable ruling from the US Court of Appeals for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in